Adoptive Cell Therapy in Solid Tumors: The Who, How, and When?
Adoptive Cell Therapy in Solid Tumors: The Who, How, and When?
While ACTs have yet to score any major wins in solid tumors beyond the early success of TILs, many early-stage clinical programs are slated to readout within the next few years.
This webinar will cover topic such as:
- What is Adoptive Cell Therapy
- Barriers To Success in Solid Tumors
- Role For Non-Curative Cell Therapy
- Role For Allogeneic
- Strategic Position for ACT
- What Exciting on the Horizon
guest panel:

Linda Pullan, Ph.D.
Pullan Consulting
Linda and her team at Pullan Consulting offer biotech and pharmaceutical companies consulting in all aspects of partnering. Linda has a Ph.D. in Biochemistry, a BS in Chemistry, and over twenty years of drug industry experience, including work on more than 75 deals. Learn More

Joel S. Sandler, P.hD.
Associate Principal, Cello Health BioConsulting
As
an Associate Principal with Defined Health, now known as Cello Health
BioConsulting, Joel provides insight to various life sciences industry
clientele (biotechnology/pharmaceutical) on fundamental issues in drug
development and partnering based on a comprehensive analysis of the key
scientific, clinical, regulatory, and commercial questions relevant to
the client’s particular situation. In previous industry roles, Joel was
instrumental in the scouting and evaluation of licensing and partnering
opportunities for various oncology assets. Prior to his BD&L
activities, Joel spent ten years focused on the discovery and
characterization of bioactive compounds for cancer and infectious
disease research at several leading academic institutions. His work has
resulted in numerous grants, fellowships, patent filings, and
peer-reviewed publications. He received his BA with honors from Cornell
University, a PhD in Organic Chemistry from UCSD, and was a NIH
Postdoctoral Fellow at The Rockefeller University.

Mythili Koneru, MD, Ph.D.
Senior Vice President, Clinical Development, Marker Therapeutics
Mythili
Koneru, MD, PhD joined Marker Therapeutics in February 2019. In her
previous role as Associate Vice President of Immuno-Oncology at Eli
Lilly and Company, Dr. Koneru designed early-stage clinical trials for
hematologic and solid tumor malignancies and was instrumental in
developing clinical trial protocols, serving as medical lead for trial
conduct. She has also served as Senior Medical Director of Early Phase
Clinical Development at Eli Lilly before she was promoted to her most
recent position. Prior to Eli Lilly, Dr. Koneru was an Oncology Fellow
in the laboratory of Dr. Renier Brentjens at Memorial Sloan-Kettering
Cancer Center, where she developed adoptive T cell therapies in both
leukemia and solid tumor malignancies in early phase clinical trials.
Dr. Koneru earned a BA in Cellular and Molecular Biology from the
University of Chicago, a PhD in Biomedical Research: Tumor Immunology
from New York University, and an MD from the Robert Wood Johnson Medical
School.

Stewart Abbot, Ph.D.
Chief Operating Officer, Adicet (formerly Fate, Celgene)
Stewart
Abbot is the Chief Operating Officer at Adicet Bio. He holds a BSc in
Biological Sciences (Edinburgh), MSc in Biomedical Engineering (Glasgow)
and PhD in Pathology (London). His academic career focused on basic and
translational science initiatives in vascular biology, pharmacology and
toxicology. He joined Amersham Biosciences in 2000 and developed
Amersham’s and, following the acquisition, General Electric’s stem
cell-based drug screening capabilities. He was head of the Molecular and
Cellular Biology research laboratory at GE’s Global Research Center
from 2004-2007. In 2007 he joined Celgene to develop novel cell-based
therapeutic candidates and subsequently the development of external
cellular therapy R&D collaborations and alliances. In 2015 he joined
Fate Therapeutics and held roles of VP translational research and chief
development officer. He joined Adicet Bio in June 2018 and his current
role oversees the development of novel genetically engineered gamma
delta T cell-based therapies.
